SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Pictured: Amgen's office in Massachusetts/iStock,
Earnings
Amid Obesity Bidding War, Amgen Believes It Can Stand Out in Crowded Space
Amgen remains confident in its obesity asset MariTide, for which it has launched a broad Phase III program.
November 5, 2025
 · 
2 min read
 · 
Tristan Manalac
A businessman hold a ladder, he tried to break through barriers to move forward
Earnings
Pfizer Fields Novo’s $10B Curveball, With Bourla Promising To Fight for Metsera
Due to the litigation Pfizer filed Friday and Monday against Metsera, Novo Nordisk and the biotech’s lead shareholder, CEO Albert Bourla was limited in what he could say. But he said Pfizer was the best fit for Metsera.
November 4, 2025
 · 
5 min read
 · 
Annalee Armstrong
Money trap and business risks, insurance concept. Vector of greedy businessman running to the bait, another man trying stop him.
Mergers & acquisitions
Novo Ups Ante In Metsera Buyout Drama With $10B Offer, Beating Pfizer’s New Bid
Both companies have submitted revised bids, with Novo’s coming in $1.9 billion higher than Pfizer’s.
November 4, 2025
 · 
1 min read
 · 
Annalee Armstrong
©Vertex Pharmaceuticals Incorporated. All Rights Reserved.
Earnings
Vertex’s New Products Dim as Analysts Eye Kidney Portfolio
The potential approval of Vertex’s IgAN therapy povetacicept in 2026 comes amid launch headwinds for the company’s non-opioid pain medicine Journavx and gene therapy Casgevy.
November 4, 2025
 · 
5 min read
 · 
Tristan Manalac
Space rocket crashed and on fire. Business failure, failed startup. Downfall of ambitious plans, flawed execution, or crisis outcomes. Volatility of startups, financial risks, or unexpected setbacks.
Duchenne muscular dystrophy
Sarepta’s DMD Exon-Skippers Fail Confirmatory Study, Stock Craters
Sarepta nevertheless plans to push for full FDA approval of Vyondys 53 and Amondys 45 based on what it said are “encouraging trends” in efficacy.
November 4, 2025
 · 
2 min read
 · 
Tristan Manalac
Female hand showing thumbs up gesture on blue background, art collage. Positive hand sign. Fashion collage in the style of Thumbs up magazine. Contemporary art. Modern design.
Rare diseases
UCB Wins First FDA Approval for Ultra-Rare Mitochondrial Disease
Kygevvi is indicated for patients with thymidine kinase 2 deficiency whose symptoms arise by 12 years of age. The disease manifests as muscle weakness and can become life-threatening in severe instances.
November 4, 2025
 · 
2 min read
 · 
Tristan Manalac
Opinion
Pharma Is Sitting on Hidden Cures. Find Your “Freda” To Unlock Them
Had Pfizer’s Freda Lewis-Hall not stepped in, SpringWorks’ rare disease treatment may never have reached patients. Pharmas can act now to help find the next Gomekli.
November 4, 2025
 · 
4 min read
 · 
Annette Bakker
A panoramic view of the Statue of Liberty framed by heavy clouds just before storm. USA, New York City.
Manufacturing
Generic Drug and API Manufacturers Call for Onshoring Incentives
Having seen Congress spend money to onshore semiconductor production, pharma groups are pushing for similar incentives for domestic drug manufacturing.
November 4, 2025
 · 
4 min read
 · 
Nick Paul Taylor
Job Trends
BioSpace 2026 Best Places to Work Spotlights Most Desirable Workplaces
BioSpace has named 50 life sciences companies to its 2026 Best Places to Work list. AbbVie, Amneal Pharmaceuticals and BridgeBio executives share what makes their organizations special.
November 4, 2025
 · 
7 min read
 · 
Angela Gabriel
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS